One approach to balance adverse events and the anti-tumor effect is the combined application of [177Lu]Lu-PSMA-617 and [225Ac]Ac-PSMA-617 with adjusted doses, known as the ‘PSMA tandem RLT’, which has been shown to be effective, especially in this challenging patient cohort [24,25,26,27,28]. Here, FOLH1 is linked to neoplasm.